Bayer Maps Out Sunharbo Rollout While Broker Targets Drift Apart

Bayer has given investors a concrete timeline for getting its newly cleared stroke medicine into circulation, alongside a debt target for the year-end and fresh signs that sell-side opinion on the stock is pulling in different directions.

Shipments of Sunharbo, the brand name for the active ingredient Asundexian, are expected to begin between mid and late November. The FDA cleared the drug to lower stroke risk in specific adults — those who have suffered an ischemic stroke or a high-risk TIA — and Bayer confirmed the narrow scope of that label. The group also expects net financial debt of EUR 28 billion to EUR 29 billion at the close of the year.

Guidance Lifted as Quarterly Figures Land

Roughly a week ago, Bayer raised its full-year forecast for EBITDA before special items to a range of EUR 9.8 billion to EUR 10.3 billion. The upgrade came on 3 November, the same day the company issued a statement on the expected timetable for the Roundup litigation. Citing CEO Bill Anderson, Reuters reported that Bayer anticipates wrapping up a settlement worth USD 7.25 billion before Christmas.

Third-quarter 2026 group revenue came in at EUR 10.1 billion, a nominal increase of 4.1%. On a currency- and portfolio-adjusted basis, growth was 1.9%. EBITDA before special items for the quarter reached EUR 1.62 billion, up 6.9% year on year.

The market took the FDA news positively, with the shares adding 3.3% in the session following the Reuters report.

Two Brokers, Two Directions

Analyst reaction to the quarterly update has been anything but uniform. Jefferies lifted its price target to EUR 48.50 from EUR 46 on the Friday after the results, keeping its "Hold" rating intact. Goldman Sachs moved the other way on the valuation scale, raising its target to EUR 66.00 from EUR 63.50 on 4 November while reaffirming a "Buy" stance. The gap between the two objectives — more than EUR 17 — underscores how divided the analyst community remains on where Bayer's equity should trade.

Pipeline News Beyond the Stroke Franchise

Regulatory progress has not been confined to Sunharbo. Bayer has also secured Chinese approval for Sevabertinib as a first-line treatment in adults with unresectable, locally advanced or metastatic HER2-mutant non-small cell lung cancer.

On the agricultural side, the company said on 4 November that it plans to bring 17 new biological products to Latin America by 2030. The lineup includes biopesticides and products designed to enhance plant performance, with the rollout spread across a multi-year window and focused squarely on that region.

Bayer will also present new data on cardiovascular disease, kidney disease and stroke at the AHA Scientific Sessions, scheduled for 6 to 9 November in Chicago — an announcement made on 3 November.